MnTE-2-PyP Porphyrin Agent for Radiation Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Prostate cancer treatment with radiation often results in side effects such as erectile dysfunction and incontinence, for which there is a need for new approaches to effectively address these issues.
Innovation Solution
Administration of the active agent MnTE-2-PyP, a porphyrin compound, to subjects undergoing pelvic radiation treatment, which is shown to protect the urogenital system and prevent radiation-induced damage, including erectile dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation treatment is administered to treat prostate cancer, then cancer is effectively treated, but erectile dysfunction and incontinence occur as side effects
Solution Approach 1:
The patent introduces an antioxidant agent as an intermediary substance that mediates between the radiation treatment and the urogenital tissues. This antioxidant agent protects the erectile nerves and surrounding tissues from radiation-induced oxidative damage, thereby preventing erectile dysfunction and incontinence while allowing the radiation to effectively treat the cancer.
2Reliability
If higher radiation doses are used to improve cancer treatment outcomes, then tumor control improves, but damage to surrounding healthy tissues increases
Solution Approach 1:
The patent converts the harmful oxidative stress caused by radiation into a beneficial protective effect by administering antioxidant agents. These agents scavenge the free radicals generated by radiation, transforming the potentially damaging oxidative environment into a controlled state that allows effective tumor treatment while protecting healthy urogenital tissues from damage.
Data Source
AI summary
An active agent for use in a method of, or for use in the preparation of a medicament for, treating or inhibiting the development of erectile dysfunction and/or incontinence following pelvic radiation treatment in a subject in need thereof, comprising administering said subject an active agent in a treatment effective amount, is described. The active agent has the general structure of Formula I:or a pharmaceutically acceptable salt thereof.